Compare CPAC & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPAC | RGNX |
|---|---|---|
| Founded | 1949 | 2008 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 919.6M | 761.9M |
| IPO Year | 2003 | 2015 |
| Metric | CPAC | RGNX |
|---|---|---|
| Price | $10.17 | $8.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $12.90 | ★ $28.75 |
| AVG Volume (30 Days) | 17.5K | ★ 810.3K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | ★ 5.40% | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | $4.49 | $58.79 |
| Revenue Next Year | N/A | $29.74 |
| P/E Ratio | $19.78 | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $5.10 | $5.04 |
| 52 Week High | $11.50 | $16.19 |
| Indicator | CPAC | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 38.35 | 40.83 |
| Support Level | $5.79 | $7.83 |
| Resistance Level | $11.37 | $9.28 |
| Average True Range (ATR) | 0.39 | 0.64 |
| MACD | -0.08 | 0.20 |
| Stochastic Oscillator | 3.85 | 23.57 |
Cementos Pacasmayo SAA is a Peruvian cement company that produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production and transportation facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.